These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 1826304)

  • 1. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction.
    Wang YX; Franco R; Gavras I; Gavras H
    J Lab Clin Med; 1991 Apr; 117(4):313-8. PubMed ID: 1826304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats.
    Mah SC; Hofbauer KG
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1028-32. PubMed ID: 2968448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective vasopressin inhibition in rats with heart failure decreases afterload and results in venodilatation.
    Raya TE; Gay RG; Goldman S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1015-20. PubMed ID: 2262890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a vasopressin antagonist with combined antipressor and antiantidiuretic activities in rats with left ventricular dysfunction.
    Mulinari RA; Gavras I; Wang YX; Franco R; Gavras H
    Circulation; 1990 Jan; 81(1):308-11. PubMed ID: 2404626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C; Haywood JR
    J Pharmacol Exp Ther; 1986 Aug; 238(2):492-6. PubMed ID: 2874211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic response to chronic blockade of vasopressin receptors in Sprague-Dawley rats.
    Mah SC; Opperman JR; Baum HP; Hofbauer KG
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1021-7. PubMed ID: 2968447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dopamine on renal receptors for arginine vasopressin.
    Mitsui T; Ogura T; Ota Z; Ogawa N
    Res Commun Chem Pathol Pharmacol; 1992 May; 76(2):131-41. PubMed ID: 1604042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
    Takeuchi M; Lee JD; Shimizu H; Ueda T
    Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Up-regulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats.
    Caltabiano S; Kinter LB
    J Pharmacol Exp Ther; 1991 Sep; 258(3):1046-54. PubMed ID: 1832462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and some pharmacological properties of new V1/V2 antagonists of arginine-vasopressin with structural changes at their N-terminals.
    Lammek B; Konieczna E; Wierzba T; Wang YX; Gavras H
    Pol J Pharmacol Pharm; 1992; 44(2):179-86. PubMed ID: 1409118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Suzuki K; Kodama M; Aizawa Y
    Biochem Pharmacol; 2007 Nov; 74(10):1466-75. PubMed ID: 17720144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
    J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between arginine vasopressin and angiotensin II receptors in the central regulation of sodium balance.
    Saad WA; Camargo LA; Antunes-Rodrigues J; Saad WA; Guarda IF; Guarda RS
    Regul Pept; 2005 Dec; 132(1-3):53-8. PubMed ID: 16198010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
    Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
    J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT; Shamshirsaz AA; McFann K; Oren RM; Schrier RW
    J Am Coll Cardiol; 2006 Apr; 47(8):1615-21. PubMed ID: 16630999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natriuretic action of neurohypophysial peptides: effects of agonists and antagonists and implication of natriuretic receptor.
    Chan WY; Hruby VJ
    J Pharmacol Exp Ther; 1988 Aug; 246(2):597-602. PubMed ID: 2969979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with cilazapril, angiotensin-converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat.
    Nishida N; Ogura T; Yamauchi T; Hosoya M; Ota Z
    Res Commun Chem Pathol Pharmacol; 1994 May; 84(2):143-52. PubMed ID: 8091000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats.
    Long JB; Martinez-Arizala A; Johnson SH; Holaday JW
    J Pharmacol Exp Ther; 1989 May; 249(2):499-506. PubMed ID: 2524587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.
    Wada K; Fujimori A; Matsukawa U; Arai Y; Sudoh K; Yatsu T; Sasamata M; Miyata K
    Eur J Pharmacol; 2005 Jan; 507(1-3):145-51. PubMed ID: 15659304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.